ConverGene invited speaker at Drug Discovery Chemistry. April 24-25, 2017 in San Diego.
ConverGene will present at Biotech Showcase during JP Morgan Healthcare conference Wednesday, January 11, 2017, 11:15 AM, Hilton San Francisco Union Square Ballroom Level Room 9
ConverGene Advances NCATS Collaboration, Biocentury Article.
ConverGene entered into an exclusive license agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. Under this agreement, ConverGene has the rights to commercialize jointly developed small molecule BET bromodomain inhibitors that have a unique core structure. November 2016.
ConverGene presents at Discovery on Target Development of Dual‐Activity Small Molecules that Target BRD4 and Dopamine Receptor D2. September 2016 in Boston.
ConverGene opens new lab and corporate HQ in Cambridge, MD. July 2016.
ConverGene scientists in conjunction with University of Maryland Baltimore researchers design new class of dual BET/PLK1 inhibitors.
Citation: ACS Med Chem Lett. 2015 May 18;6(7):764-9.
doi: 10.1021/acsmedchemlett.5b00084. eCollection 2015.
ConverGene receives $25,000 IMPACT grant award from the Montgomery County Department of Economic Development to further the progress of its BET inhibitor program.
ConverGene executives attend the EpiGenetics Congress July 21-23, 2015 in Boston.
ConverGene executives attend the BIO International Convention June 15-18, 2015 in Philadelphia.
ConverGene executives attend the Epigenetics and Cancer Conference January 25-30, 2015 in Keystone, Colorado.
ConverGene executives attend the Discovery on Target meeting October 8-10, 2014 in Boston.
ConverGene selected to receive a Maryland Industrial Partnership (MIPS) Award (MIPS). The funds will be used for the development of a bromodomain inhibitor.
ConverGene executives attend Bio2014 June 23-26, 2014 in San Diego.
ConverGene executives attend the International Molecular Medicine Tri-Conference February 9-14, 2014 in San Francisco .
ConverGene raises $850,000 in the latest round of seed investment, bringing the total capital raised to $1.1 million.
ConverGene receives $75,000 TEDCO grant to broaden medicinal chemistry efforts in partnership with the University of Maryland.
ConverGene enters into a Lease and Master Services Agreement with Noble Life Sciences, Inc., a Montgomery County, Maryland-based preclinical drug development services company. Noble provides infrastructure, laboratory, and R&D services, to ConverGene.